Kim Sablich
Net Worth
Last updated:
What is Kim Sablich net worth?
The estimated net worth of Ms. Kim Sablich is at least $8,509,421 as of 8 Mar 2023. She owns shares worth $3,659,560 as insider, has earned $1,371,941 from insider trading and has received compensation worth at least $3,477,920 in Jazz Pharmaceuticals plc.
What is the salary of Kim Sablich?
Ms. Kim Sablich salary is $869,480 per year as Executive Vice President & GM of North America in Jazz Pharmaceuticals plc.
How old is Kim Sablich?
Ms. Kim Sablich is 56 years old, born in 1969.
What stocks does Kim Sablich currently own?
As insider, Ms. Kim Sablich owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | Executive Vice President & GM of North America | 30,560 | $119.75 | $3,659,560 |
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Kim Sablich insider trading
Jazz Pharmaceuticals plc
Ms. Kim Sablich has made 9 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently she sold 1,752 units of JAZZ stock worth $244,264 on 8 Mar 2023.
The largest trade she's ever made was exercising 2,748 units of JAZZ stock on 11 Nov 2021. As of 8 Mar 2023 she still owns at least 30,560 units of JAZZ stock.
Jazz Pharmaceuticals key executives
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC:
- Dr. Robert Iannone M.D. (58) Executive Vice President of R&D and Chief Medical Officer
- Mr. Bruce C. Cozadd (61) Co-Founder, Chairman & Chief Executive Officer
- Mr. Daniel N. Swisher Jr. (62) Pres
- Ms. Kim Sablich (56) Executive Vice President & GM of North America
- Ms. Renee D. Gala (53) Executive Vice President & Chief Financial Officer